abt-20230419

0001628280-23-012020.txt : 20230419 0001628280-23-012020.hdr.sgml : 20230419 20230419072516 ACCESSION NUMBER: 0001628280-23-012020 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230419 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230419 DATE AS OF CHANGE: 20230419 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-02189 FILM NUMBER: 23828457 BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 2246676100 MAIL ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 8-K 1 abt-20230419.htm 8-K abt-20230419

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

_______________________________________________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

April 19, 2023

Date of Report (Date of earliest event reported)

ABBOTT LABORATORIES

(Exact name of registrant as specified in charter)

_______________________________________________________

Illinois

1-2189

36-0698440

(State or other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification  No.)

_______________________________________________________

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (224) 667-6100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered Pursuant to Section 12(b) of the Act:


Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common Shares, Without Par Value	ABT	New York Stock Exchange Chicago Stock Exchange, Inc.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition

On April 19, 2023, Abbott Laboratories announced its results of operations for the first quarter 2023.

Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, restructuring actions, cost reduction initiatives, a voluntary recall, certain regulatory costs, tax benefits associated with specified items, net tax expense as a result of the resolution of various tax positions related to prior years, and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott’s management internally assesses performance. Abbott’s management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott’s results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott’s management also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.

Item 9.01 Financial Statements and Exhibits


Exhibit No.						Exhibit

99.1						Press Release dated April 19, 2023 (furnished pursuant to Item 2.02).

104						Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	ABBOTT LABORATORIES

Date: April 19, 2023	By:	/s/ Robert E. Funck, Jr.
		Robert E. Funck, Jr.
		Executive Vice President, Finance and Chief Financial Officer

EX-99.1 2 abt-2023q1xexhibitx991.htm EX-99.1 Document

Exhibit 99.19.1


			News Release

Abbott Reports First-Quarter 2023 Results; Increases Outlook For Underlying Base Business

–Sales of $9.7 billion driven by strong underlying base business performance

–Reported sales decreased 18.1 percent due to anticipated decline in COVID-19 testing-related sales versus prior year

–Organic sales growth for underlying base business of 10.0 percent, led by Medical Devices, Established Pharmaceuticals and Nutrition

ABBOTT PARK, Ill., April 19, 2023 — Abbott today announced financial results for the first quarter ended March 31, 2023.

•First-quarter GAAP diluted EPS of $0.75 and adjusted diluted EPS of $1.03, which excludes specified items.

•Projected full-year 2023 diluted EPS from continuing operations on a GAAP basis of $3.05 to $3.25 remains unchanged.

•Projected full-year adjusted EPS from continuing operations of $4.30 to $4.50 remains unchanged and now reflects an increased outlook for the underlying base business offset by a lower forecasted earnings contribution from COVID-19 testing-related sales.

•Abbott now projects full-year 2023 organic sales growth, excluding COVID-19 testing-related sales1, of at least high single-digits2 and COVID-19 testing-related sales of approximately $1.5 billion.

•In January, Abbott announced U.S. Food and Drug Administration (FDA) approval of Navitor®, its second-generation transcatheter aortic valve implantation system, for people with severe aortic stenosis who are at high risk for surgery.

•In March, data was presented at the American College of Cardiology Scientific Sessions showing Abbott's TriClip® system was superior to current medical therapy in treating patients with severe tricuspid regurgitation, or a leaky tricuspid heart valve.

•In March, Abbott's market-leading FreeStyle Libre® continuous glucose monitoring system received U.S. FDA clearance for integration with automated insulin delivery systems. Abbott is partnering with leading insulin pump manufacturers to integrate their systems with FreeStyle Libre 2 and FreeStyle Libre 3 as soon as possible.

"Our first-quarter results reflect a very strong start to the year," said Robert B. Ford, chairman and chief executive officer, Abbott. "Growth in our underlying base businesses accelerated, including particularly strong results in Medical Devices, Established Pharmaceuticals and Nutrition."

-- more --

Page 1 of 15

FIRST-QUARTER BUSINESS OVERVIEW

Management believes that measuring sales growth rates on an organic basis, which excludes the impact of foreign exchange, as well as the impact of exiting the pediatric nutrition business in China, is an appropriate way for investors to best understand the core underlying performance of the business.

Management further believes that measuring sales growth rates on an organic basis excluding COVID-19 tests is an appropriate way for investors to best understand underlying base business performance as the COVID-19 pandemic shifts to an endemic state, resulting in significantly lower expected demand for COVID-19 tests.

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

Total Company

Reported Sales


Sales 1Q23 ($ in millions)	Total Company	Nutrition	Diagnostics	Established Pharmaceuticals	Medical Devices
U.S.	3,928	812	1,335	—	1,778
International	5,819	1,155	1,353	1,189	2,122
Total reported	9,747	1,967	2,688	1,189	3,900


% Change vs. 1Q22
U.S.	(20.4)	19.9	(50.8)	n/a	15.1
International	(16.4)	(5.1)	(46.9)	3.7	3.5
Total reported	(18.1)	3.8	(48.9)	3.7	8.5

Organic Sales


% Change vs. 1Q22	Total Company	Nutrition	Diagnostics	Established Pharmaceuticals	Medical Devices
Reported	(18.1)	3.8	(48.9)	3.7	8.5
Impact of foreign exchange	(3.3)	(3.9)	(1.8)	(7.4)	(3.9)
Impact of business exit	(0.3)	(2.6)	—	—	—
Organic	(14.5)	10.3	(47.1)	11.1	12.4
Impact of COVID-19 testing sales3	(24.5)	—	(51.5)	—	—
Organic excluding COVID-19 tests	10.0	10.3	4.4	11.1	12.4

U.S.	12.6	19.9	0.3	n/a	15.1
International	8.6	4.8	6.8	11.1	10.4

n/a = Not Applicable.

Refer to page 13 for a reconciliation of adjusted historical revenue to reported revenue.

-- more --

Page 2 of 15

Nutrition

Reported Sales


Sales 1Q23 ($ in millions)	Total	Pediatric	Adult
U.S.	812	459	353
International	1,155	465	690
Total reported	1,967	924	1,043


% Change vs. 1Q22
U.S.	19.9	36.1	3.9
International	(5.1)	(8.6)	(2.6)
Total reported	3.8	9.2	(0.5)

Organic Sales


% Change vs. 1Q22	Total	Pediatric	Adult
Reported	3.8	9.2	(0.5)
Impact of foreign exchange	(3.9)	(2.8)	(4.7)
Impact of business exit	(2.6)	(6.4)	—
Organic	10.3	18.4	4.2

U.S.	19.9	36.1	3.9
International	4.8	5.3	4.4

Worldwide Nutrition sales increased 3.8 percent on a reported basis and 10.3 percent on an organic basis in the first quarter. Refer to page 13 for a reconciliation of adjusted historical revenue to reported revenue.

In Pediatric Nutrition, global sales increased 9.2 percent on a reported basis and 18.4 percent on an organic basis. In the U.S., sales growth of 36.1 percent includes the impact of lower sales in the first quarter of the prior year due to a voluntary recall of certain infant formula products. Following a temporary manufacturing stoppage of these products, Abbott subsequently restarted production last year and continues to make good progress recovering market share in this business.

In Adult Nutrition, global sales decreased 0.5 percent on a reported basis and increased 4.2 percent on an organic basis, which was led by strong global growth of Ensure®, Abbott's market-leading complete and balanced nutrition brand.

-- more --

Page 3 of 15

Diagnostics

Reported Sales


Sales 1Q23 ($ in millions)	Total	Core Laboratory	Molecular	Point of Care	Rapid Diagnostics *
U.S.	1,335	289	47	93	906
International	1,353	893	100	41	319
Total reported	2,688	1,182	147	134	1,225


% Change vs. 1Q22
U.S.	(50.8)	7.7	(72.7)	2.9	(58.4)
International	(46.9)	(2.5)	(59.7)	9.2	(76.3)
Total reported	(48.9)	(0.2)	(65.0)	4.7	(65.3)

Organic Sales


% Change vs. 1Q22	Total	Core Laboratory	Molecular	Point of Care	Rapid Diagnostics *
Reported	(48.9)	(0.2)	(65.0)	4.7	(65.3)
Impact of foreign exchange	(1.8)	(5.3)	(1.0)	(1.0)	(0.8)
Organic	(47.1)	5.1	(64.0)	5.7	(64.5)
Impact of COVID-19 testing sales3	(51.5)	(2.0)	(39.2)	—	(72.5)
Organic excluding COVID-19 tests	4.4	7.1	(24.8)	5.7	8.0

U.S.	0.3	9.0	(36.7)	2.9	(0.9)
International	6.8	6.5	(18.9)	12.7	23.2

*The Acelis Connected Health business was internally transferred from Rapid Diagnostics to Heart Failure on January 1, 2023. As a result, $29 million of sales for the first quarter of 2022 were moved from Rapid Diagnostics to Heart Failure.

As expected, Diagnostics sales growth in the first quarter was negatively impacted by year-over-year declines in COVID-19 testing-related sales3. Worldwide COVID-19 testing sales were $730 million in the first quarter of 2023 compared to $3.304 billion in the first quarter of the prior year.

Excluding COVID-19 testing-related sales, global Diagnostics sales increased 0.2 percent on a reported basis and increased 4.4 percent on an organic basis. Organic sales growth, excluding COVID-19 testing-related sales, was led by Core Laboratory, Point of Care and Rapid Diagnostics. In Molecular Diagnostics, growth was negatively impacted by lower demand for seasonal respiratory testing compared to significantly higher-than-usual demand in the first quarter of the prior year.

-- more --

Page 4 of 15

Established Pharmaceuticals

Reported Sales


Sales 1Q23 ($ in millions)	Total	Key Emerging Markets	Other
U.S.	—	—	—
International	1,189	912	277
Total reported	1,189	912	277


% Change vs. 1Q22
U.S.	n/a	n/a	n/a
International	3.7	0.7	15.0
Total reported	3.7	0.7	15.0

Organic Sales


% Change vs. 1Q22	Total	Key Emerging Markets	Other
Reported	3.7	0.7	15.0
Impact of foreign exchange	(7.4)	(7.6)	(6.8)
Organic	11.1	8.3	21.8

U.S.	n/a	n/a	n/a
International	11.1	8.3	21.8

Established Pharmaceuticals sales increased 3.7 percent on a reported basis and 11.1 percent on an organic basis in the first quarter.

Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 0.7 percent on a reported basis and 8.3 percent on an organic basis, led by growth in Brazil, China and Southeast Asia, and across several therapeutic areas, including cardiometabolic, respiratory and central nervous system/pain management.

-- more --

Page 5 of 15

Medical Devices

Reported Sales


Sales 1Q23 ($ in millions)	Total	Rhythm Management	Electro- physiology	Heart Failure *	Vascular	Structural Heart	Neuro-modulation	Diabetes Care
U.S.	1,778	260	238	218	218	210	155	479
International	2,122	267	267	63	399	251	41	834
Total reported	3,900	527	505	281	617	461	196	1,313


% Change vs. 1Q22
U.S.	15.1	4.4	10.0	11.3	4.8	10.5	8.4	39.7
International	3.5	(3.2)	(1.0)	16.6	(2.7)	13.7	13.5	6.5
Total reported	8.5	0.4	3.9	12.4	(0.2)	12.2	9.4	16.6

Organic Sales


% Change vs. 1Q22	Total	Rhythm Management	Electro- physiology	Heart Failure *	Vascular	Structural Heart	Neuro-modulation	Diabetes Care
Reported	8.5	0.4	3.9	12.4	(0.2)	12.2	9.4	16.6
Impact of foreign exchange	(3.9)	(3.6)	(4.9)	(1.2)	(4.1)	(4.2)	(1.8)	(4.4)
Organic	12.4	4.0	8.8	13.6	3.9	16.4	11.2	21.0

U.S.	15.1	4.4	10.0	11.3	4.8	10.5	8.4	39.7
International	10.4	3.7	7.8	22.3	3.4	21.4	22.5	12.9

Worldwide Medical Devices sales increased 8.5 percent on a reported basis and 12.4 percent on an organic basis in the first quarter, including double-digit organic sales growth in both the U.S. and internationally.

Sales growth was led by double-digit organic growth in Diabetes Care, Structural Heart, Heart Failure and Neuromodulation. Several recently launched products and new indications contributed to the strong performance, including Amplatzer® Amulet®, Navitor, TriClip, Aveir® and CardioMEMS®.

In Electrophysiology, internationally, sales grew double-digits on a reported basis and high-teens on an organic basis in Europe, which was partially offset by soft market conditions in China during the first several weeks of the first quarter.

In Diabetes Care, FreeStyle Libre sales were $1.2 billion, which included U.S. growth of approximately 50 percent.

-- more --

Page 6 of 15

ABBOTT'S EARNINGS-PER-SHARE GUIDANCE

Abbott projects full-year 2023 diluted earnings per share from continuing operations under GAAP of $3.05 to $3.25. Abbott forecasts specified items for the full-year 2023 of $1.25 per share primarily related to intangible amortization, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $4.30 to $4.50 for the full-year 2023.

ABBOTT DECLARES 397TH CONSECUTIVE QUARTERLY DIVIDEND

On February 17, 2023, the board of directors of Abbott declared the company's quarterly dividend of $0.51 per share. Abbott's cash dividend is payable May 15, 2023, to shareholders of record at the close of business on April 14, 2023.

Abbott has increased its dividend payout for 51 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

About Abbott:

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 115,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.

Abbott will live-webcast its first-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.

-- more --

Page 7 of 15

— Private Securities Litigation Reform Act of 1995 —

A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2022, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.


Abbott Financial: Scott Leinenweber, 224-668-0791 Michael Comilla, 224-668-1872 Ryan Aliff, 224-667-2299			Abbott Media: Karen Twigg May, 224-668-2681 Kate Dyer, 224-668-9965

1For the full-year 2022, COVID-19 testing-related sales were $8.368 billion and total worldwide sales were $43.653 billion.

2Abbott has not provided the related GAAP financial measure for organic sales growth, excluding COVID-19 testing-related sales, on a forward-looking basis because the company is unable to predict the impact of foreign exchange due to the unpredictability of future changes in foreign exchange rates, which could significantly impact reported sales growth.

3Diagnostic sales and COVID-19 testing-related sales in 2023 and 2022 are summarized below:


	Sales 1Q23			COVID Tests Sales 1Q23
($ in millions)	U.S.	Int'l	Total		U.S.	Int'l	Total
Total Diagnostics	1,335	1,353	2,688		608	122	730
Core Laboratory	289	893	1,182		2	4	6
Molecular	47	100	147		10	10	20

Rapid Diagnostics	906	319	1,225		596	108	704


	Sales 1Q22			COVID Tests Sales 1Q22
($ in millions)	U.S.	Int'l	Total		U.S.	Int'l	Total
Total Diagnostics	2,712	2,545	5,257		1,988	1,316	3,304
Core Laboratory	268	916	1,184		5	23	28
Molecular	172	248	420		114	132	246

Rapid Diagnostics	2,181	1,344	3,525		1,869	1,161	3,030

-- more --

Page 8 of 15

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

First Quarter Ended March 31, 2023 and 2022

(in millions, except per share data)

(unaudited)


	1Q23	1Q22	% Change
Net Sales	$9,747	$11,895	(18.1)

Cost of products sold, excluding amortization expense	4,331	4,987	(13.2)
Amortization of intangible assets	491	512	(4.0)
Research and development	654	697	(6.2)
Selling, general, and administrative	2,762	2,787	(0.9)
Total Operating Cost and Expenses	8,238	8,983	(8.3)

Operating Earnings	1,509	2,912	(48.2)

Interest expense, net	52	117	(56.1)
Net foreign exchange (gain) loss	6	(3)	n/m
Other (income) expense, net	(111)	(78)	41.5
Earnings before taxes	1,562	2,876	(45.7)
Taxes on earnings	244	429	(43.0)	1)

Net Earnings	$1,318	$2,447	(46.1)

Net Earnings excluding Specified Items, as described below	$1,815	$3,077	(41.0)	2)

Diluted Earnings per Common Share	$0.75	$1.37	(45.3)

Diluted Earnings per Common Share, excluding Specified Items, as described below	$1.03	$1.73	(40.5)	2)

Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options	1,752	1,775

NOTES:

See tables on page 11 for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes on the following page.

-- more --

Page 9 of 15

1)2023 Taxes on Earnings includes the recognition of approximately $22 million of net tax expense as a result of the resolution of various tax positions related to prior years.

2022 Taxes on Earnings includes the recognition of approximately $30 million of net tax expense as a result of the resolution of various tax positions related to prior years and approximately $30 million in excess tax benefits associated with share-based compensation.

2)2023 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $497 million, or $0.28 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and other net expenses.

2022 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $630 million, or $0.36 per share, for intangible amortization, charges related to a voluntary recall and other net expenses primarily associated with acquisitions.

-- more --

Page 10 of 15

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information

First Quarter Ended March 31, 2023 and 2022

(in millions, except per share data)

(unaudited)


	1Q23
	As Reported (GAAP)		Specified Items		As Adjusted

Intangible Amortization	$	491	$	(491)	$	—
Gross Margin	4,925		520		5,445
R&D	654		(26)		628
SG&A	2,762		(2)		2,760

Earnings before taxes	1,562		548		2,110
Taxes on Earnings	244		51		295
Net Earnings	1,318		497		1,815
Diluted Earnings per Share	$	0.75	$	0.28	$	1.03

Specified items reflect intangible amortization expense of $491 million and other net expenses of $57 million associated with restructuring actions, costs associated with acquisitions and other expenses. See page 14 for additional details regarding specified items.


	1Q22
	As Reported (GAAP)		Specified Items		As Adjusted

Intangible Amortization	$	512	$	(512)	$	—
Gross Margin	6,396		636		7,032
R&D	697		(33)		664
SG&A	2,787		(39)		2,748
Other (income) expense, net	(78)		(15)		(93)
Earnings before taxes	2,876		723		3,599
Taxes on Earnings	429		93		522
Net Earnings	2,447		630		3,077
Diluted Earnings per Share	$	1.37	$	0.36	$	1.73

Specified items reflect intangible amortization expense of $512 million and other net expenses of $211 million that includes costs associated with a product recall, acquisitions and other net expenses. See page 15 for additional details regarding specified items.

-- more --

Page 11 of 15

A reconciliation of the first-quarter tax rates for 2023 and 2022 is shown below:


	1Q23
($ in millions)	Pre-Tax Income		Taxes on Earnings		Tax Rate
As reported (GAAP)	$	1,562	$	244	15.6	%	1)
Specified items	548		51
Excluding specified items	$	2,110	$	295	14.0	%


	1Q22
($ in millions)	Pre-Tax Income		Taxes on Earnings		Tax Rate
As reported (GAAP)	$	2,876	$	429	14.9	%	2)
Specified items	723		93
Excluding specified items	$	3,599	$	522	14.5	%

1)2023 Taxes on Earnings includes the recognition of approximately $22 million of net tax expense as a result of the resolution of various tax positions related to prior years.

2)2022 Taxes on Earnings includes the recognition of approximately $30 million of net tax expense as a result of the resolution of various tax positions related to prior years and approximately $30 million in excess tax benefits associated with share-based compensation.

-- more --

Page 12 of 15

Abbott Laboratories and Subsidiaries

Non-GAAP Revenue Reconciliation

First Quarter Ended March 31, 2023 and 2022

($ in millions)

(unaudited)


	1Q23			1Q22			% Change vs. 1Q22
								Non-GAAP
	Abbott Reported	Impact from business exit (a)	Adjusted Revenue	Abbott Reported	Impact from business exit (a)	Adjusted Revenue	Reported	Adjusted	Organic
Total Company	9,747	(8)	9,739	11,895	(52)	11,843	(18.1)	(17.8)	(14.5)
U.S.	3,928	—	3,928	4,937	—	4,937	(20.4)	(20.4)	(20.4)
Intl	5,819	(8)	5,811	6,958	(52)	6,906	(16.4)	(15.9)	(10.2)

Total Nutrition	1,967	(8)	1,959	1,894	(52)	1,842	3.8	6.4	10.3
U.S.	812	—	812	677	—	677	19.9	19.9	19.9
Intl	1,155	(8)	1,147	1,217	(52)	1,165	(5.1)	(1.5)	4.8

Pediatric Nutrition	924	(8)	916	847	(52)	795	9.2	15.4	18.4
U.S.	459	—	459	338	—	338	36.1	36.1	36.1
Intl	465	(8)	457	509	(52)	457	(8.6)	0.2	5.3

(a) Reflects the impact of exiting the pediatric nutrition business in China. This action was initiated in December 2022.

-- more --

Page 13 of 15

Abbott Laboratories and Subsidiaries

Details of Specified Items

First Quarter Ended March 31, 2023

(in millions, except per share data)

(unaudited)


	Acquisition or Divestiture- related (a)		Restructuring and Cost Reduction Initiatives (b)		Intangible Amortization		Other (c)		Total Specifieds
Gross Margin	$	5	$	21	$	491	$	3	$	520
R&D	(4)		1		—		(23)		(26)
SG&A	(4)		(4)		—		6		(2)
Other (income) expense, net	(6)		—		—		6		—
Earnings before taxes	$	19	$	24	$	491	$	14	548
Taxes on Earnings (d)									51
Net Earnings									$	497
Diluted Earnings per Share									$	0.28

The table above provides additional details regarding the specified items described on page 11.

a)Acquisition-related expenses include legal and other costs related to business acquisitions as well as integration costs, which represent incremental costs directly related to integrating acquired businesses.

b)Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.

c)Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.

d)Reflects the net tax benefit associated with the specified items.

-- more --

Page 14 of 15

Abbott Laboratories and Subsidiaries

Details of Specified Items

First Quarter Ended March 31, 2022

(in millions, except per share data)

(unaudited)


	Acquisition or Divestiture- related (a)		Restructuring and Cost Reduction Initiatives (b)		Intangible Amortization		Other (c)		Total Specifieds
Gross Margin	$	21	$	(6)	$	512	$	109	$	636
R&D	(2)		(1)		—		(30)		(33)
SG&A	(11)		—		—		(28)		(39)
Other (income) expense, net	(7)		—		—		(8)		(15)
Earnings before taxes	$	41	$	(5)	$	512	$	175	723
Taxes on Earnings (d)									93
Net Earnings									$	630
Diluted Earnings per Share									$	0.36

The table above provides additional details regarding the specified items described on page 11.

a)Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for the integration of systems, processes and business activities.

b)Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. The Gross Margin amount includes a credit associated with the charges taken in the second quarter of 2021 for a restructuring plan related to Abbott's manufacturing network for COVID-19 diagnostic tests.

c)Other includes charges related to a voluntary recall within the Nutrition segment and incremental costs to comply with the European Union's Medical Device (MDR) and In Vitro Diagnostics Medical Device (IVDR) Regulations for previously approved products.

d)Reflects the net tax benefit associated with the specified items, excess tax benefits associated with share-based compensation and net tax expense as a result of the resolution of various tax positions related to prior years.

###

Page 15 of 15

EX-101.SCH 3 abt-20230419.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 abt-20230419_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 abt-20230419_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Soliciting Material Soliciting Material Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Document Information [Line Items] Document Information [Line Items] Title of 12(b) Security Title of 12(b) Security Exchange [Domain] Exchange [Domain] Amendment Flag Amendment Flag NYSE CHICAGO, INC. NYSE CHICAGO, INC. [Member] Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Document Period End Date Document Period End Date Entity Listings, Exchange [Axis] Entity Listings, Exchange [Axis] Entity Tax Identification Number Entity Tax Identification Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, City or Town Entity Address, City or Town Local Phone Number Local Phone Number Written Communications Written Communications Cover [Abstract] NEW YORK STOCK EXCHANGE, INC. NEW YORK STOCK EXCHANGE, INC. [Member] Document Type Document Type Document Information [Table] Document Information [Table] Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 6 abt-20230419_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 7 image.jpg begin 644 image.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT

Cover	Apr. 19, 2023
Document Information [Line Items]
Document Type	8-K
Document Period End Date	Apr. 19, 2023
Entity Registrant Name	ABBOTT LABORATORIES
Entity Incorporation, State or Country Code	IL
Entity File Number	1-2189
Entity Tax Identification Number	36-0698440
Entity Address, Address Line One	100 Abbott Park Road
Entity Address, City or Town	Abbott Park
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60064-6400
City Area Code	224
Local Phone Number	667-6100
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Entity Central Index Key	0000001800
Amendment Flag	false
NYSE CHICAGO, INC.
Document Information [Line Items]
Title of 12(b) Security	Common Shares, Without Par Value
Trading Symbol	ABT
Security Exchange Name	CHX
NEW YORK STOCK EXCHANGE, INC.
Document Information [Line Items]
Title of 12(b) Security	Common Shares, Without Par Value
Trading Symbol	ABT
Security Exchange Name	NYSE

XML 9 abt-20230419_htm.xml IDEA: XBRL DOCUMENT 0000001800 2023-04-19 2023-04-19 0000001800 exch:XNYS 2023-04-19 2023-04-19 0000001800 exch:XCHI 2023-04-19 2023-04-19 0000001800 false NYSE CHX 8-K 2023-04-19 ABBOTT LABORATORIES IL 1-2189 36-0698440 100 Abbott Park Road Abbott Park IL 60064-6400 224 667-6100 false false false false Common Shares, Without Par Value Common Shares, Without Par Value ABT ABT NYSE CHX false 2023-04-19 EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 3 22 1 false 2 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://abbott.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName - abt-20230419.htm 4 abt-20230419.htm abt-20230419.xsd abt-20230419_def.xml abt-20230419_lab.xml abt-20230419_pre.xml abt-2023q1xexhibitx991.htm http://xbrl.sec.gov/dei/2022 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "abt-20230419.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 28 }, "contextCount": 3, "dts": { "definitionLink": { "local": [ "abt-20230419_def.xml" ] }, "inline": { "local": [ "abt-20230419.htm" ] }, "labelLink": { "local": [ "abt-20230419_lab.xml" ] }, "presentationLink": { "local": [ "abt-20230419_pre.xml" ] }, "schema": { "local": [ "abt-20230419.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 2, "nsprefix": "abt", "nsuri": "http://abbott.com/20230419", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abt-20230419.htm", "contextRef": "ifbffff8f51a24cc9b62c1f93223b6ef4_D20230419-20230419", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://abbott.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abt-20230419.htm", "contextRef": "ifbffff8f51a24cc9b62c1f93223b6ef4_D20230419-20230419", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityListingsExchangeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Listings, Exchange [Axis]", "terseLabel": "Entity Listings, Exchange [Axis]" } } }, "localname": "EntityListingsExchangeAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_ExchangeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.", "label": "Exchange [Domain]", "terseLabel": "Exchange [Domain]" } } }, "localname": "ExchangeDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "exch_XCHI": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NYSE CHICAGO, INC. [Member]", "terseLabel": "NYSE CHICAGO, INC." } } }, "localname": "XCHI", "nsuri": "http://xbrl.sec.gov/exch/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "exch_XNYS": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NEW YORK STOCK EXCHANGE, INC. [Member]", "terseLabel": "NEW YORK STOCK EXCHANGE, INC." } } }, "localname": "XNYS", "nsuri": "http://xbrl.sec.gov/exch/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 17 0001628280-23-012020-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-23-012020-xbrl.zip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end